Trump appointed judge hears case that could ban abortion pill
Dean Rachel Rebouche joins KALW’s Your Call to discuss a court decision that could reverse FDA approval of mifepristone, one of two drugs used in self-managed abortions. Read More
Dean Rachel Rebouche joins KALW’s Your Call to discuss a court decision that could reverse FDA approval of mifepristone, one of two drugs used in self-managed abortions. Read More
Uproar over Walgreens’ decision not to dispense abortion pills in some states where they are legal is reflective of the chaos unleashed by Dobbs, says Dean Rebouche. She says other companies are watching to see what happens next in the “court of public opinion.” Read More
Georgia’s new ban on abortion after six weeks will create a “very tight timeframe” for pregnant people to obtain a legal abortion, says Dean Rebouche. Read More
Dean Rebouche notes that Walgreens’ approach to dispensing abortion pills is necessarily cautious, given the “dynamic and frankly confusing legal landscape.” Read More
Dean Rebouche says the furor over Walgreens’ decision not to dispense abortion pills in some states where they are legal is “what we are in store for” as conflict centers on access to the medication. Read More
Prof. Laura Little on parody as the Supreme Court’s favored child and the Onion’s now-famous amicus brief in this episode of Criminal, a podcast about crime. Listen
The Nicaraguan government has stripped 222 political dissidents of their citizenship in what Prof. Peter Spiro calls an act of “bainshment” in clear violation of international law. Read More
Could a Texas judge block access to abortion pills nationwide? Dean Rebouche discusses a new lawsuit and explains what’s at stake. Read More
Luxury brand Hermes prevailed in its trademark suit against MetaBirkins NFTs creator Mason Rothschild, setting the first federal precedent for litigation about the digital assets. Prof. Paul Gugliuzza explains why. Read More
Dean Rebouche explains what’s at stake in conflicting opinions over the FDA’s authority to approve mifepristone, and how the issue could impact federal agencies across the board. Read More